Trial Profile
A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Pharmacyclics
- 23 May 2018 Planned End Date changed from 1 Mar 2018 to 1 Aug 2018.
- 01 Nov 2017 Planned End Date changed from 1 Nov 2017 to 1 Mar 2018.
- 19 May 2017 Planned End Date changed from 1 Jul 2016 to 1 Nov 2017.